Welcome to Jun Lab

Integrated Genomics and Precision Medicine for Alzheimer Disease

Dr. Gyungah Jun is a globally renowned Alzheimer’s disease (AD) geneticist and an expert in analysis of “big data”. She has been a key member of the Alzheimer’s Disease Genetics Consortium (ADGC) and the International Genomics of Alzheimer’s Project (IGAP) to identify AD risk genes within APOE genotype subgroups. She has led and conducted innovative analysis approaches to identify distinct genetic signatures contributing to Alzheimer’s disease risk in APOE4-positive vs. APOE4-negative subgroups. She is working on development of a novel therapeutic concept to mimic the protective mechanism of the APOE ε2 allele. She has unique industry experience, served as the Director and Head of Neurogenetics and Integrated Genomics in Alzheimer’s disease therapeutics. Translational research for AD therapeutics remains her main focus.

Under Dr. Jun’s direction, the lab is actively involved in large coordinated national initiatives for AD therapeutics empowered by artificial intelligence (AI) and machine learning (ML) that utilizes high-throughput human genome data. The lab also leads efforts on genome guided drug discovery for AD including innovative drug discovery, drug repurposing, and platform development for open collaboration with academia and industry. Active research areas include Ultrascale Machine Learning to Empower Discovery in Alzheimer’s Disease Biobanks (AI4AD), Asian Cohort for Alzheimer’s Disease (ACAD), APOE in the Predisposition to (APOE-Biomarker), Protection from and Prevention of Alzheimer’s Disease, Genomic and Biological Studies of APOE e2 in Alzheimer Disease (APOE2), and Precision Monitoring and Assessment in the Framingham Study: Cognitive, MRI, Genetic and Biomarker Precursors of AD & Dementia (FHS-BAP).

72 E Concord St, Boston, MA 02118